Association between lactate dehydrogenase and the risk of venous thromboembolism and mortality in critically ill patients: a retrospective cohort study
This retrospective cohort study of 15,999 critically ill patients using MIMIC-IV data demonstrates that elevated serum lactate dehydrogenase (LDH) levels are independently associated with an increased risk of incident venous thromboembolism and higher hospital and ICU mortality, suggesting LDH may serve as a practical biomarker for early risk stratification in this population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the high-stakes environment of an intensive care unit, where patients are fighting for their lives against severe illness, the body often sends out distress signals that are difficult to interpret. One of the most dangerous complications these patients face is venous thromboembolism, a condition where blood clots form in the veins and can travel to the lungs, causing sudden and often fatal blockages. While doctors know that critical illness creates a perfect storm for these clots due to immobility and inflammation, predicting exactly who will develop them remains a difficult challenge. To solve this, medical researchers often look for biomarkers, which are measurable substances in the blood that act as early warning signs. Among these, lactate dehydrogenase is a common enzyme found in nearly every cell of the body. Under normal conditions, it stays safely inside the cells, but when tissues are injured, starved of oxygen, or dying, the cell walls break down and release this enzyme into the bloodstream. Because its presence signals that something is wrong with the body's tissues, it has long been used to gauge the severity of various diseases, but its specific role in predicting blood clots and death in the general intensive care population has remained unclear.
A team of researchers set out to clarify this relationship by analyzing a massive collection of real-world medical data. They turned to the MIMIC-IV database, a public repository containing detailed electronic health records from hundreds of thousands of intensive care patients. The researchers focused on adults who had stayed in the intensive care unit for at least a day, ensuring they had enough time for complications to develop, and who did not already have blood clots when they arrived. They specifically looked for patients who had a blood test for lactate dehydrogenase taken within the first 24 hours of their stay. After filtering the data to include only these specific cases, they ended up with a group of nearly 16,000 patients. To make sense of the wide range of enzyme levels, the team divided these patients into four equal groups, or quartiles, based on how much lactate dehydrogenase was in their blood, from the lowest levels to the highest.
The researchers then compared the health outcomes of these groups to see if the amount of enzyme in the blood could predict what would happen next. They tracked two main things: whether the patients developed new blood clots during their hospital stay, and whether they survived their time in the hospital and the intensive care unit. The results showed a clear and direct link between higher enzyme levels and worse outcomes. Patients in the group with the highest levels of lactate dehydrogenase were significantly more likely to develop blood clots than those in the group with the lowest levels. Even after the researchers carefully adjusted for other factors that could influence the results, such as the patient's age, the severity of their illness, and other existing health conditions, the association remained strong. The data indicated that having high levels of this enzyme was an independent risk factor, meaning the enzyme level itself carried information about the risk of clotting that was not explained by other known causes.
The connection to survival was even more pronounced. The study found that as the levels of lactate dehydrogenase rose, the chances of a patient surviving their hospital stay and their time in the intensive care unit dropped significantly. Patients in the highest quartile faced a much greater risk of death compared to those with the lowest levels. The researchers used statistical methods to map out the relationship between the enzyme levels and the risk of death, finding that the risk did not just go up in a straight line but increased in a complex, non-linear pattern as the levels climbed. This suggests that the body's response to severe injury, as measured by this enzyme, is a powerful indicator of how well a patient will fare. The study also looked at whether this relationship held true for different types of patients, such as those with heart disease or infections, and found that while the strength of the link varied slightly in some specific groups, the overall trend of higher enzyme levels predicting higher risk was consistent across the board.
While the study provides strong evidence from a large group of patients, the authors note that their findings come from a retrospective analysis, meaning they looked back at data that had already been collected rather than following patients forward in a controlled experiment. This approach is excellent for spotting patterns and generating hypotheses, but it cannot prove that the enzyme itself causes the clots or the death; it only shows that they happen together. The researchers also pointed out that because the data came from a single database, the results might not apply perfectly to every hospital or every type of patient population around the world. Despite these limitations, the study offers a compelling new perspective on a common blood test. It suggests that lactate dehydrogenase, a marker already measured for many reasons, could serve as a practical tool for doctors to identify which critically ill patients are at the highest risk for life-threatening blood clots and poor survival, potentially allowing for earlier and more targeted interventions to protect these vulnerable individuals.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.